To perform differential chromatin accessibility analysis between mutant and wild-type p53 tumours, we focused on two cancer subtypes, breast infiltrating ductal carcinoma and colon adenocarcinoma, which have sufficient numbers of samples in both groups. The gene discussed is TP53; the disease is cancer.